UnitedHealth Group Updates Business Outlook Ahead of Investor Conference
28 Noviembre 2022 - 03:15PM
Business Wire
UnitedHealth Group (NYSE: UNH) issued financial guidance ahead
of its annual Investor Conference which takes place on November 29,
beginning at 8:00 a.m. ET.
UnitedHealth Group revenues for 2022 are now expected to be
approximately $324 billion. Net earnings are expected to be $20.85
to $21.05 per share and adjusted net earnings of $21.85 to $22.05
per share, as announced in the third quarter earnings release.
Adjusted net earnings only excludes the after-tax non-cash
amortization expense pertaining to acquisition-related intangible
assets.
UnitedHealth Group will also introduce its 2023 outlook which
includes revenues of $357 billion to $360 billion, net earnings of
$23.15 to $23.65 per share, and adjusted net earnings of $24.40 to
$24.90 per share. Cash flows from operations are expected to range
from $27 billion to $28 billion.
The Company will stream the Investor Conference presentation and
management question-and-answer portion of this meeting on its
Investor Relations page at www.unitedhealthgroup.com. Meeting
materials and a replay of the conference will be available on the
Investor Relations page.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being
company with a mission to help people live healthier lives and help
make the health system work better for everyone through two
distinct and complementary businesses. Optum delivers care aided by
technology and data, empowering people, partners and providers with
the guidance and tools they need to achieve better health.
UnitedHealthcare offers a full range of health benefits, enabling
affordable coverage, simplifying the health care experience and
delivering access to high-quality care. Visit UnitedHealth Group at
www.unitedhealthgroup.com and follow @UnitedHealthGrp on
Twitter.
Non-GAAP Financial
Information
This news release presents non-GAAP financial information
provided as a complement to the results provided in accordance with
accounting principles generally accepted in the United States of
America (“GAAP”). Adjusted net earnings exclude amortization
expense of approximately $1.35 and $1.65 per share and the related
tax impacts of $0.35 and $0.40 per share for years ending December
31, 2021 and 2022, respectively, pertaining to acquisition-related
intangible assets.
Forward-Looking
Statements
The statements, estimates, projections, guidance or outlook
contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor”
provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,”
“outlook,” “plan,” “project,” “should” and similar expressions
identify forward-looking statements. These statements may contain
information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could
differ materially from those that management expects, depending on
the outcome of certain factors including: risks associated with
public health crises, large-scale medical emergencies and
pandemics, such as the COVID-19 pandemic; our ability to
effectively estimate, price for and manage medical costs; new or
changes in existing health care laws or regulations, or their
enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and
achieve improvement in quality scores impacting revenue; reductions
in revenue or delays to cash flows received under government
programs; changes in Medicare, the CMS star ratings program or the
application of risk adjustment data validation audits; failure to
maintain effective and efficient information systems or if our
technology products do not operate as intended; cyberattacks, other
privacy/data security incidents, or our failure to comply with
related regulations; failure to protect proprietary rights to our
databases, software and related products; risks and uncertainties
associated with our businesses providing pharmacy care services;
competitive pressures, including our ability to develop and deliver
innovative products to health care payers and expand access to
virtual care; changes in or challenges to our public sector
contract awards; failure to develop and maintain satisfactory
relationships with health care payers, physicians, hospitals and
other service providers; failure to attract, develop, retain, and
manage the succession of key employees and executives; the impact
of potential changes in tax laws and regulations (including any
increase in the U.S. income tax rate applicable to corporations);
failure to achieve targeted operating cost productivity
improvements; increases in costs and other liabilities associated
with litigation, government investigations, audits or reviews;
failure to manage successfully our strategic alliances or complete
or receive anticipated benefits of strategic transactions;
fluctuations in foreign currency exchange rates; downgrades in our
credit ratings; our investment portfolio performance; impairment of
our goodwill and intangible assets; and our ability to obtain
sufficient funds from our regulated subsidiaries or from external
financings to fund our obligations, maintain our debt to total
capital ratio at targeted levels, maintain our quarterly dividend
payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and
certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with
the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By
their nature, forward-looking statements are not guarantees of
future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or
quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior
communications. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. We do not undertake to update or revise any
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221128005744/en/
Investors: Zack Sopcak Zack.Sopcak@uhg.com 952-936-7215
Media: Eric Hausman Eric.Hausman@uhg.com 952-936-3963
UnitedHealth (NYSE:UNH)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
UnitedHealth (NYSE:UNH)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024